Jump to main content
Jump to site search

Issue 11, 2013
Previous Article Next Article

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

Author affiliations

Abstract

Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).

Graphical abstract: The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

Back to tab navigation

Article information


Submitted
15 Oct 2012
Accepted
04 Dec 2012
First published
05 Dec 2012

Org. Biomol. Chem., 2013,11, 1766-1800
Article type
Perspective

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

B. J. Deadman, M. D. Hopkin, I. R. Baxendale and S. V. Ley, Org. Biomol. Chem., 2013, 11, 1766
DOI: 10.1039/C2OB27003J

Social activity

Search articles by author

Spotlight

Advertisements